Company Analysis
Sign in

Corcept Therapeutics Incorporated (CORT)

Nasdaq: CORT · Pharmaceutical Preparations · Redwood City, CA · filing with the SEC since 2001
Full chart Alerts Compare
Grade7.3
◀ Past 8.3● Present 8.0▶ Future 5.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

131 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Corcept Therapeutics Incorporated’s names, not what it holds today.

Patents granted
131
131 utility, 1976 to Dec 31, 2025
Granted in 2025
10
Against 19 in 2024 and 16 in 2023
Applications published
188
21 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals48
Organic fine chemistry13
Medical technology6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Corcept Therapeutics Incorporated its own name
US, as the owner printed on each patent
131 granted
83 published
Corcept Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
105 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,440,487Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonistPharmaceuticalsCorcept Therapeutics Incorporated
Oct 7, 202512,433,882Treatments for amyotrophic lateral sclerosis using dazucorilantPharmaceuticalsCorcept Therapeutics Incorporated
Jul 29, 202512,370,188Formulations of dazucorilant, a glucocorticoid receptor modulatorPharmaceuticalsCorcept Therapeutics Incorporated
Jul 29, 202512,370,175Glucocorticoid receptor modulators to treat pancreatic cancerPharmaceuticalsCorcept Therapeutics Incorporated
Jun 24, 202512,336,985Methods for shrinking pituitary tumorsMedical technologyCorcept Therapeutics Incorporated
May 6, 202512,290,551Methods for imaging and treatment of somatostatin-receptor positive tumorsPharmaceuticalsCorcept Therapeutics Incorporated
Apr 29, 202512,285,425Glucocorticoid receptor modulators to treat cervical cancerPharmaceuticalsCorcept Therapeutics Incorporated
Apr 1, 202512,263,169Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulatorsPharmaceuticalsCorcept Therapeutics Incorporated
Feb 18, 202512,226,417Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonistsPharmaceuticalsCorcept Therapeutics Incorporated
Feb 18, 202512,226,412Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorsPharmaceuticalsCorcept Therapeutics Incorporated
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0381178TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANTPharmaceuticalsCorcept Therapeutics Incorporated
Dec 11, 20252025/0375433METHODS FOR SHRINKING PITUITARY TUMORSMedical technologyCorcept Therapeutics Incorporated
Nov 27, 20252025/0360125METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMSPharmaceuticalsCorcept Therapeutics Incorporated
Oct 9, 20252025/0312312GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCERPharmaceuticalsCorcept Therapeutics Incorporated
Sep 25, 20252025/0295650GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT CERVICAL CANCERPharmaceuticalsCorcept Therapeutics Incorporated
Sep 18, 20252025/0288580TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANTPharmaceuticalsCorcept Therapeutics Incorporated
Jul 10, 20252025/0221995FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTSPharmaceuticalsCorcept Therapeutics Incorporated
Jul 3, 20252025/0214971QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTSOrganic fine chemistryCorcept Therapeutics, Inc.
Jun 19, 20252025/0195543Optimizing Mifepristone AbsorptionPharmaceuticalsCorcept Therapeutics Incorporated
May 8, 20252025/0145620METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORSPharmaceuticalsCorcept Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 29 · Organic fine chemistry 10 · Medical technology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CORT · research, not advice